Clinical Efficacy of Decitabine/Azacitidine in Combination with HAG in the Treatment of Elderly Patients with Acute Myeloid Leukemia
PDF

Keywords

Decitabine
Azacitidine
HAG
Elderly patients with acute myeloid leukaemia

DOI

10.26689/jcnr.v6i4.4046

Abstract

This study was conducted to investigate the clinical effect of combining decitabine/azacitidine with HAG in the treatment of single elderly patients with acute myeloid leukemia. Patients in Shaanxi Provincial People’s Hospital were selected for this study from January 2020 to January 2022, and all of the patients were elderly patients with acute myeloid leukemia. Around 23 patients were selected for this study, subsequently the patients were divided into two groups; Group A contained 11 patients and was given decitabine in combination with HAG; and Group B contained 12 patients, and was given azacitidine in combination with HAG. This study showed that the treatment effective rates of patients in both groups were 90.91% and 58.33%, respectively, with a small difference (P>0.05) in the data comparison. The incidence of adverse reactions in the two groups was 63.64% and 16.67%, respectively, with the incidence in group B is significantly (P<0.05) lower compared with group A. Meanwhile, compared with group B, patients in group A had a significantly (p<0.05) shorter mean time to WBC normalization, higher HB and PLT levels, lower WBC levels were lower, all the survival duration times were longer, and subpopulation indicators of peripheral blood T lymphocytes were more in line with normal values. In summary, this study demonstrated that the combination of azacitidine and HAG therapies for the treatment of elderly patients with acute myeloid leukemia is more effective, furthermore can reduce significantly the incidence of adverse treatment effects in patients.

References

Qi HY, Wang WS, Lan JP, 2021, Clinical Efficacy of Decitabine Combined with Low-Dose IA Regimen in the Treatment of Elderly Patients with Acute Myeloid leukemia. Zhejiang Medicine, 43(20): 2194–2197.

Wang Y, Wang X, Ren S, 2020, Clinical Efficacy of Decitabine + AG Regimen Combined with Fostering Detoxification and Eliminating Stasis in the Treatment of Elderly Patients with Acute Myeloid Leukemia. Journal of China Medical University, 49(5): 414–418.

Ji X, Gao A, Tian P, 2021, Comparison of the Efficacy and Safety of Different Chemotherapy Regimens in Combination with Decitabine for the Treatment of Acute Myeloid Leukemia in the Elderly. Cancer Progress, 19(18): 1910–1912.

Deng LJ, Li Y, Qiao YH, et al., 2020, Clinical Application of Demethylating Drugs in Acute Myeloid Leukemia. Chinese Journal of New Drugs and Clinics, 39(6): 329–334.

Wang Q, 2020, Clinical Effects of Decitabine Combined with CAG Regimen in Elderly Patients with Acute Myeloid Leukemia. Wisdom Health, 6(24):188–190.

Liu F, Du MZ, Li G, et al., 2020, Efficacy of Low-Dose Decitabine Combined with Reduced HAG Regimen in the Treatment of Elderly Hypoproliferative Acute Myeloid Leukemia. Modern Medical Oncology, 28(4): 626–629.

Qi Y, Zhao M, Xiao X, et al., 2020, Clinical Efficacy of Decitabine Combined with Reduced FLAG Regimen in the Treatment of Elderly Patients with High-Risk Acute Myeloid Leukemia. Chinese Journal of Experimental Hematology, 28(5): 1440–1444.

Wang J, Lei Q, 2020, Clinical Efficacy of Decitabine Combined with Low-Dose HAG Regimen in the Treatment of Elderly Patients with Acute Myeloid Leukemia. Clinical Medicine Research and Practice, 5(10): 33–34.

Jia X, Chen L, Li G, et al., 2021, A Case of Relapsed Refractory Acute Myeloid Leukemia Treated with Decitabine Combined with Venetoclax. Chinese Clinical Oncology, 48(3): 162.

Hong P, Fu J, Feng W, et al., 2020, Efficacy and Safety Analysis of Decitabine Combined with CHG Regimen in the Treatment of Acute Myeloid Leukemia in the Elderly. Chinese Journal of Modern Medicine, 30(23): 90–94.

Yuan XY, 2020, A Comparative Study on the Recent Efficacy and Safety of Azacitidine and Decitabine in the Treatment of Myelodysplastic Syndrome in the Elderly. The Great Physician, 5(19): 102–104.

Hong P, Fu J, Feng W, et al., 2020, Efficacy and Safety Analysis of Decitabine Combined with CHG Regimen in the Treatment of Acute Myeloid Leukemia in the Elderly. Chinese Journal of Modern Medicine, 30(23): 84–88.

Yu N, Tang YN, Zhang RAM, 2020, Advances in Clinical Molecular Studies of Azacitidine and Decitabine in the Treatment of Hematologic Tumors. China Hospital Drug Evaluation and Analysis, 20(4): 510–512.

Zhang X, Yang HQ, Qin J, et al., 2021, A Case of Refractory Acute Monocytic Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation with Venecla Combined with Azacitidine and Review of the Literature Leukemia. Lymphoma, 30(11): 692–694.

Xie SL, Liu LP, Li HL, 2021, Clinical Observation of Azacitidine in the Treatment of Medium- and High-Risk Myelodysplastic Syndrome. Medical Theory and Practice, 34(19): 3372–3375.

Mao JP, Xue LG, Jia T, et al., 2020, Efficacy of Decitabine Combined with Modified ECAG Regimen in the Treatment of Elderly Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Not Suitable for Standard Regimen Chemotherapy. Chinese Journal of Physicians, 22(12): 1905–1908.

Xu Z, Chen Y, Wu Mei, et al., 2020, Clinical Analysis of Decitabine Combined with CAG Regimen in the Treatment of Acute Myeloid Leukemia in the Elderly. Pharmacology Research, 39(8): 491–493 + 496.

Cheng YY, Hu M, Yang HP, 2021, Clinical Efficacy of Decitabine Combined with Reduced Dose Chemotherapy in the Treatment of Primary Acute Myeloid Leukemia in the Elderly. Capital Food and Medicine, 28(9): 48–50.

Zhang Y, Chen P, Li H, et al., 2021, Efficacy of Decitabine Combined with HA Regimen for the Induction Treatment of Acute Myeloid Leukemia in the Elderly. China Medical Journal, 56(1): 91–93.

Zhang J, 2020, Analysis of the Efficacy of Treating Elderly Patients with Acute Myeloid Leukemia with Low-Dose Decitabine Combined with a Modified CAG Regimen. Contemporary Medicine Series, 18(1): 99–100.